Human Igg1 Kappa Monoclonal Antibody Against Crlf2

4 trials

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

1 Sponsors

12 Countries

Phase II

Phase II: 4

Indications tested

Asthmatic crisis 2 Chronic rhinosinusitis with nasal polyps 1 Chronic obstructive pulmonary disease 1

Sponsors using this IMP

Upstream Bio Inc. 4

All trials

4 total

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended

2024-519469-23-00 Phase II 6 countries Upstream Bio Inc.
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Phase II 11 countries Upstream Bio Inc.
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps on a Bac… Ended

2023-508231-31-00 Phase II 4 countries Upstream Bio Inc.
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Phase II 6 countries Upstream Bio Inc.

Showing 1–4 of 4 trials

← All drugs A–Z